Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 2
2006 1
2007 1
2008 1
2009 2
2010 3
2011 2
2012 5
2013 3
2014 2
2015 3
2016 9
2017 6
2018 6
2019 6
2020 4
2021 7
2022 7
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Results by year

Filters applied: . Clear all
Page 1
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone.
Choi EM, Lacarra B, Afolabi MO, Ale BM, Baiden F, Bétard C, Foster J, Hamzé B, Schwimmer C, Manno D, D'Ortenzio E, Ishola D, Keita CM, Keshinro B, Njie Y, van Dijck W, Gaddah A, Anumendem D, Lowe B, Vatrinet R, Lawal BJ, Otieno GT, Samai M, Deen GF, Swaray IB, Kamara AB, Kamara MM, Diagne MA, Kowuor D, McLean C, Leigh B, Beavogui AH, Leyssen M, Luhn K, Robinson C, Douoguih M, Greenwood B, Thiébaut R, Watson-Jones D; EBOVAC-3/EBL2005 Study Team. Choi EM, et al. Among authors: baiden f. Lancet Glob Health. 2023 Nov;11(11):e1743-e1752. doi: 10.1016/S2214-109X(23)00410-2. Lancet Glob Health. 2023. PMID: 37858585 Free article. Clinical Trial.
The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen.
Manno D, Patterson C, Drammeh A, Tetteh K, Kroma MT, Otieno GT, Lawal BJ, Soremekun S, Ayieko P, Gaddah A, Kamara AB, Baiden F, Afolabi MO, Tindanbil D, Owusu-Kyei K, Ishola D, Deen GF, Keshinro B, Njie Y, Samai M, Lowe B, Robinson C, Leigh B, Drakeley C, Greenwood B, Watson-Jones D. Manno D, et al. Among authors: baiden f. Vaccines (Basel). 2023 Aug 2;11(8):1317. doi: 10.3390/vaccines11081317. Vaccines (Basel). 2023. PMID: 37631885 Free PMC article.
Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial.
Manno D, Bangura A, Baiden F, Kamara AB, Ayieko P, Kallon J, Foster J, Conteh M, Connor NE, Koroma B, Njie Y, Borboh P, Keshinro B, Lawal BJ, Kroma MT, Otieno GT, Deen AT, Choi EM, Balami AD, Gaddah A, McLean C, Luhn K, Adetola HH, Deen GF, Samai M, Lowe B, Robinson C, Leigh B, Greenwood B, Watson-Jones D. Manno D, et al. Among authors: baiden f. Lancet Infect Dis. 2023 Mar;23(3):352-360. doi: 10.1016/S1473-3099(22)00594-1. Epub 2022 Oct 20. Lancet Infect Dis. 2023. PMID: 36273490 Free article. Clinical Trial.
Prevalence of malaria and helminth infections in rural communities in northern Sierra Leone, a baseline study to inform Ebola vaccine study protocols.
Baiden F, Fleck S, Leigh B, Ayieko P, Tindanbil D, Otieno T, Lawal B, Tehtor M, Rogers M, Odeny L, Hodges MH, Sonnie M, Samai M, Ishola D, Lowe B, Watson-Jones D, Greenwood B. Baiden F, et al. PLoS One. 2022 Jul 6;17(7):e0270968. doi: 10.1371/journal.pone.0270968. eCollection 2022. PLoS One. 2022. PMID: 35793331 Free PMC article.
Estimating causes of death where there is no medical certification: evolution and state of the art of verbal autopsy.
Chandramohan D, Fottrell E, Leitao J, Nichols E, Clark SJ, Alsokhn C, Cobos Munoz D, AbouZahr C, Di Pasquale A, Mswia R, Choi E, Baiden F, Thomas J, Lyatuu I, Li Z, Larbi-Debrah P, Chu Y, Cheburet S, Sankoh O, Mohamed Badr A, Fat DM, Setel P, Jakob R, de Savigny D. Chandramohan D, et al. Among authors: baiden f. Glob Health Action. 2021 Oct 26;14(sup1):1982486. doi: 10.1080/16549716.2021.1982486. Glob Health Action. 2021. PMID: 35377290 Free PMC article. Review.
Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra Leone.
Manno D, Ayieko P, Ishola D, Afolabi MO, Rogers B, Baiden F, Serry-Bangura A, Bah OM, Köhn B, Swaray I, Owusu-Kyei K, Otieno GT, Kowuor D, Tindanbil D, Smout E, Robinson C, Keshinro B, Foster J, Gallagher K, Lowe B, Douoguih M, Leigh B, Greenwood B, Watson-Jones D. Manno D, et al. Among authors: baiden f. Emerg Infect Dis. 2022 Mar;28(3):734-738. doi: 10.3201/eid2803.211496. Emerg Infect Dis. 2022. PMID: 35202536 Free PMC article.
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.
Ishola D, Manno D, Afolabi MO, Keshinro B, Bockstal V, Rogers B, Owusu-Kyei K, Serry-Bangura A, Swaray I, Lowe B, Kowuor D, Baiden F, Mooney T, Smout E, Köhn B, Otieno GT, Jusu M, Foster J, Samai M, Deen GF, Larson H, Lees S, Goldstein N, Gallagher KE, Gaddah A, Heerwegh D, Callendret B, Luhn K, Robinson C, Leyssen M, Greenwood B, Douoguih M, Leigh B, Watson-Jones D; EBL3001 study group. Ishola D, et al. Among authors: baiden f. Lancet Infect Dis. 2022 Jan;22(1):97-109. doi: 10.1016/S1473-3099(21)00125-0. Epub 2021 Sep 13. Lancet Infect Dis. 2022. PMID: 34529963 Free PMC article. Clinical Trial.
66 results